201 related articles for article (PubMed ID: 23796582)
1. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials.
Mullane KM; Cornely OA; Crook DW; Golan Y; Louie TJ; Miller MA; Josephson MA; Gorbach SL
Am J Nephrol; 2013; 38(1):1-11. PubMed ID: 23796582
[TBL] [Abstract][Full Text] [Related]
2. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.
Cornely OA; Miller MA; Fantin B; Mullane K; Kean Y; Gorbach S
J Clin Oncol; 2013 Jul; 31(19):2493-9. PubMed ID: 23715579
[TBL] [Abstract][Full Text] [Related]
3. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
4. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
[TBL] [Abstract][Full Text] [Related]
5. Effect of age on treatment outcomes in Clostridium difficile infection.
Louie TJ; Miller MA; Crook DW; Lentnek A; Bernard L; High KP; Shue YK; Gorbach SL
J Am Geriatr Soc; 2013 Feb; 61(2):222-30. PubMed ID: 23379974
[TBL] [Abstract][Full Text] [Related]
6. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
7. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
Cornely OA
Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
[TBL] [Abstract][Full Text] [Related]
8. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.
Mullane KM; Miller MA; Weiss K; Lentnek A; Golan Y; Sears PS; Shue YK; Louie TJ; Gorbach SL
Clin Infect Dis; 2011 Sep; 53(5):440-7. PubMed ID: 21844027
[TBL] [Abstract][Full Text] [Related]
12. Advanced chronic kidney disease: a strong risk factor for Clostridium difficile infection.
Kim SC; Seo MY; Lee JY; Kim KT; Cho E; Kim MG; Jo SK; Cho WY; Kim HK
Korean J Intern Med; 2016 Jan; 31(1):125-33. PubMed ID: 26767866
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
14. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences.
Johnson S; Gerding DN
Clin Infect Dis; 2013 Jan; 56(2):309-10. PubMed ID: 23024296
[No Abstract] [Full Text] [Related]
15. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.
Sears P; Ichikawa Y; Ruiz N; Gorbach S
Ann N Y Acad Sci; 2013 Jul; 1291():33-41. PubMed ID: 23672600
[TBL] [Abstract][Full Text] [Related]
16. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies.
Parmar SR; Bhatt V; Yang J; Zhang Q; Schuster M
J Oncol Pharm Pract; 2014 Jun; 20(3):172-82. PubMed ID: 23804627
[TBL] [Abstract][Full Text] [Related]
17. The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer.
Esmaily-Fard A; Tverdek FP; Crowther DM; Ghantoji SS; Adachi JA; Chemaly RF
Pharmacotherapy; 2014 Nov; 34(11):1220-5. PubMed ID: 25164587
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology, diagnosis and treatment of Clostridium difficile infection.
Bassetti M; Villa G; Pecori D; Arzese A; Wilcox M
Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1405-23. PubMed ID: 23253319
[TBL] [Abstract][Full Text] [Related]
19. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
20. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.
Gerding DN; Meyer T; Lee C; Cohen SH; Murthy UK; Poirier A; Van Schooneveld TC; Pardi DS; Ramos A; Barron MA; Chen H; Villano S
JAMA; 2015 May; 313(17):1719-27. PubMed ID: 25942722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
